The upcoming report from Cencora (COR) is expected to reveal quarterly earnings of $3.50 per share, indicating an increase of 6.7% compared to the year-ago period. Analysts forecast revenues of $78.12 billion, representing an increase of 8.1% year over year.Over the last 30 days, there has been an upward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of t ...

Cencora (COR) is slated to report first-quarter fiscal 2025 results on Feb. 05, before market open.In the last reported quarter, the company delivered an earnings surprise of 4.05%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.97%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $78.12 billion, up 8.1% from the prior-year quarter’s level. The consensus mark f ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.Shares of this Zacks Rank #2 (Buy) company have risen 10.8% in the past six months against the industry’s 11% decline. The S&P 500 Index has increased 12.3% in the same time frame.Cencora is one of the world’s largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs ...

Nationally ranked stock picker for 30 years. Victory Formation and Bottom Fishing Club quant-sort pioneer.....Paul Franke is a private investor and speculator with 38 years of trading experience. Mr. Franke was Editor and Publisher of the Maverick Investor® newsletter during the 1990s, widely quoted by CNBC®, Barron’s®, the Washington Post® and Investor’s Business Daily®. Paul was consistently ranked among top investment advisors nationally for stock market and commodity macro views by Timer Digest® during ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |------------------------------|-----------------------------|----------------------|-------------------------------| | | | | | | FOR THE TRANSITION | PERIOD | FRO ...

If you are looking for a profitable portfolio of stocks offering the best of value and growth investing, try the growth at a reasonable price or GARP strategy.The strategy helps investors gain exposure to undervalued stocks with impressive prospects. Unlike a blend strategy, a portfolio that uses GARP investing is expected to include stocks that offer the best value and growth investing. Cencora, Inc. (COR) , Raymond James Financial (RJF) and Cintas Corporation (CTAS) are some GARP stocks that hold promise. ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 19.7% against 8.9% decline of the industry. The S&P 500 composite has risen 24.5% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical service companies. It focuses on providing drug distribut ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cencora (COR) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Cencora is a member of our Medical group, which includes 1023 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individua ...

Cencora, Inc. (COR) reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.34, which beat the Zacks Consensus Estimate of $3.21 by 4%. The bottom line also improved 16.8% year over year.GAAP EPS was 2 cents, down 98.8% from the year-ago period.The significant decline in the fiscal fourth-quarter GAAP EPS has likely resulted from increased operating expenses. This was led by $418 million of goodwill impairment charges related to PharmaLex, along with increased litigation and opioid-relat ...

On Wednesday, Cencora, Inc.’s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.  The sales jump reflects a 15.7% increase in revenue within U.S. Healthcare Solutions and a 5.5% increase in revenue within International Healthcare Solutions.The company reported adjusted EPS of $3.34, up 16.8% year over year, beating the consensus of $3.22.Also Read: Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health InsurersConc ...